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Review Article
Current status of immunotherapy for the treatment of lung cancer
Sanjay Murala, Vamsi Alli, Daniel Kreisel, Andrew E Gelman, Alexander S Krupnick
Thoracic Immunobiology Laboratory, Departments of Surgery, Pathology and Immunology of Washington University School of Medicine, St.
Louis, Missouri, USA

ABSTRACT

Key Words:

Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive
immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant
melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based
therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated limited or no
success (3,4) but recent trials of antigen-specific cancer immunotherapy have shown early therapeutic potential
and are now being rigorously evaluated on a larger scale (5). In this communication we briefly review the
historic aspects of immune based therapy for solid cancer, describe therapeutic strategies aimed at targeting
lung cancer, and discuss limitations of current therapy and future directions of this field.
lung cancer; immunotherapy
J Thorac Dis 2010; 2: 237-244. DOI: 10.3978/j.issn.2072-1439.2010.11.6

Does the immune system influence
the development and progression of
cancer?
Clinical data from immunosuppressed organ transplant recipients
or patients with HIV clearly demonstrates an increase in viral
mediated cancers such as cervical carcinoma (Human Papilloma
Virus), hepatocellular carcinoma (Hepatitis B and C), as well
as Burkitt’s Lymphoma (Epstein Barr Virus) (6-8). While such
data maybe understandable in light of the defined role that the
immune system plays in elimination of oncogenic viruses, large
population based studies of solid organ transplant recipients
also demonstrate an increase in multiple types of malignancies
with no known viral etiology, such as malignant melanoma,
renal cell carcinoma and non-Burkitt’s lymphoma (9,10). Such
“experiments of nature” form the basis for the theory of cancer
immunosurveillance, which proposes that a healthy immune
system can protect an individual from the development and
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uncontrolled growth of malignancies (11). The theory of cancer
immunoediting furthers the immunosurveillance theory and
suggests that the immune system can both control the growth
as well as shape the phenotype of cancer. It is thus possible that
once a clinically evident tumor develops in an immunocompetent
individual it has been sculpted to avoid immunorecognition, akin
to bacterial drug resistance that develops in those treated with
long-term antibiotics (12). Many studies in small animals with
genetically engineered immune defects support observational
human data and provide an experimental platform for studying
the role of the tumor immune response.
Unfortunately few human or animal studies have focused on
the role of the immune system in surveillance for lung cancer.
Such lack of data leads to controversy in this field. A recently
published European study of immunosuppressed patients
demonstrated no increase in lung cancer in kidney or liver
transplant recipients but an increase in those receiving a heart
allograft (13). Based on this data it is possible to conclude that
in the population as a whole immunosurveillance for lung cancer
may not occur. Alternatively one could conceive that differences
in cancer incidence may be unmasked only in patients with
a significant smoking history, such as those requiring heart
transplantation for coronary artery disease. Other observational
studies, however, do not demonstrate an increase in lung cancer
in heart transplant recipients, despite an increase in other
cancers such as malignant melanoma and cervical carcinoma
(14). Similar controversy exists in small animal models of lung
cancer. Kobayashi and colleagues, for example, demonstrated
that the incidence of chemically induced lung cancer is similar in
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immunocompetent and T cell deficient littermates while other
investigators, using similar methodology, have demonstrated the
importance of T cells in immunosurveillance for fibrosarcoma
(15-17). Based on these and other data one must conclude
that the existence of immunosurveillance for lung cancer is not
rigorously supported by clinical or animal data. Thus, unlike
clinical trials of immune based therapy for melanoma and renal
cell carcinoma, the rationale for immunotherapy in the treatment
of lung cancer deserves more background investigation. Since
lung cancer, especially non small cell lung cancer (NSCLC), is
the leading form of cancer related death (18,19), funding and
execution of such trials is a critical priority to our field.

History of tumor immunotherapy
The first organized trials of immunotherapy can be rightfully
credited to a New York Surgeon William Coley, whose line
of clinical research began in the 1890’s with an anecdotal
observation that the facial sarcoma of a German immigrant, Fred
Stein, miraculously regressed after a post-operative bacterial
infection. This incident initiated Coley’s clinical research as he
started to infect cancer patients with various bacterial isolates
(20). Coley’s findings led to the creation of “Coley's toxin”, a
concoction derived from cultures of Streptoccocus pyogens and
Serratia marcasens (21). Only in the 1990’s was it defined that
the anti-tumor effects of these bacterial toxins were the result
of “tumor necrosis factor” produced by recipient macrophages
rather then direct tumor toxicity (22). Multiple other strategies
to stimulate an antitumor immune response have been similarly
tried using bacterial products such as Corynebacterium parvum
(23). The modern era of tumor immunotherapy can be traced to
the use of adaptive cell therapy described in 1985 by Rosenberg
and colleagues (24). In this classic translational trial, based
directly on preclinical animal models, autologous lymphokineactivated killer cells were administered along with recombinant
interleukin-2 (IL-2) to patients with advanced cancer. Despite
failure of all other therapy prior to entry into this trial, cancer
regression was documented in 11 out of 25 patients. While the
response of malignant melanoma was most striking, including
one complete and long-lasting responder, tumor regression
or stability was noted in other cancers as well, including
one patient with lung cancer. Based on the overwhelming
response documented in patients with metastatic melanoma,
significant effort has focused on immunotherapy for this specific
malignancy. Furthermore, the majority of clinical efforts in other
types of malignancies are based on data generated from the
melanoma model.

Definition of tumor immunotherapy
Passive immunotherapy is defined as administration of an
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immunologically active agent to a patient that is made outside
the body. In theory such a system does not rely on the function
of the host’s own immune system to have its effect. Currently
used examples of such therapy include the administration of
monoclonal antibodies (25) or adaptive cell therapy, which
is described below (26). Active immunotherapy focuses on
stimulating the hosts own immune system to eradicate cancer,
whether by vaccination with tumor antigens and an adjuvant,
non specific immunomodulation using bacterial products,
or targeting negative regulatory receptors that prevent the
development of the tumor immune response. As described
above some of the earliest trials and successes of immunotherapy
involved active immunotherapy in the form of non-specific
immunomodulation using bacterial products to stimulate the
immune response. Despite the early success reported by Coley,
others were unable to obtain a similar degree of success using
Coley’s toxin (27). This resulted in the search for another form
of immune stimulation. In 1908 Albert Calmette and Camille
Guerin of the Pasteur Institute in Lille, France began work with
the attenuated form of bovine tuberculosis, Mycobacterium
bovis, or Bacille Calmette-Guérin (BCG), in an effort to develop
a vaccine for human tuberculosis. Their work combined with the
startling observation in 1929 by Raymond Pearl that patients
with tuberculosis had a lower rate of cancer led to investigation
into the use of live attenuated BCG as a form of tumor
immunotherapy (28,29). To date BCG remains a clinically
accepted and approved form of therapy for bladder cancer, with
responses equal to if not superior to chemotherapy (30).
Advances in understanding immune regulation have resulted
in the development of more defined methods of stimulating
the immune system. Based on the central role that IL-2 plays
in orchestrating inflammatory responses, and its success in
mediating regression of some forms of human cancer (24,31,32),
it was approved for human use in 1992 for renal cell carcinoma
and in 1998 for malignant melanoma. Recent work in elucidating
pathways used by malignancies to downregulate the immune
response has led to experimental and clinical success in the
palliation of metastatic malignant melanoma (33).
The administration of cancer vaccines, in the form of active
immunotherapy, is based on the notion that malignancies
express either mutated proteins that can be recognized as
foreign antigens, overexpress normal proteins, or reexpress fetal
antigens not present in the normal adult tissue. Such tumor
associated antigens (TAA) form the basis for recognition of
malignant tissue as a “foreign” entity (34,35). As a large number
of such antigens can be presented to T lymphocytes by antigenpresenting cells, a major effort has focused on immunizing
cancer patients using either whole cells, proteins, or synthetic
peptides in order to stimulate a tumor immune response. This
form of active immunotherapy is also known as antigen-specific
immunotherapy. Similar to other forms of immune based
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therapy, the greatest success has been demonstrated in clinical
trials for malignant melanoma, especially when combined with
efforts to ameliorate pathways that downregulate the immune
response. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is
receptor expressed on the surface of T cells that interacts with
dendritic cell surface co-stimulatory molecules that then act
to inhibit T cell activation (36). This interaction occurs in a
competitive manner to the engagement of other T cell receptors,
such as CD80 and CD86, which provide the signal necessary for
the initiation of the T cell response. To this end the humanized
form of anti-CTLA-4 IgG antibody (ipilimumab) was recently
demonstrated to foster an anti-melanoma immune response
leading to a significant survival advantage for patients with
unresectable stage III or IV melanoma previously unresponsive
to conventional therapy (33). Further encouraging results were
reported in several large randomized clinical trials for prostate
cancer, utilizing a vaccine targeting prostatic acid phosphatase
(37,38), and follicular lymphoma using a vaccine unique for
each individual patient (39).
Adoptive cell transfer is a form of passive immunotherapy that
involves identification, isolation, expansion and subsequential
re-infusion of autologous lymphocytes with anti-tumor activity
into patients. This form of therapy has been used with or without
administration of appropriate growth factors to enhance T cell
survival and expansion in vivo. Such an approach also has the
theoretic advantage that identification and isolation of only a few
tumor reactive lymphocytes is sufficient for therapy as these cells
can be expanded significantly in ex vivo prior to reinfusion (40).
The genetic modification of isolated cells and the introduction of
T cell receptors with high avidity for tumor specific antigens also
creates exciting therapeutic possibilities (26).

Immunotherapy for lung cancer
Active immunotherapy for lung cancer can be traced back to
observational studies suggesting that, similar to the sarcoma
observations of Coley, local inflammatory changes may influence
the prognosis of lung cancer (41,42). Enthusiasm for BCG
therapy as adjuvant or neoadjuvant therapy was tempered early
on by the lack of demonstrated efficacy in several clinical trials.
While a 1981 series reported a decrease in local recurrence after
adjuvant post-operative BCG in patients with early stage disease,
these results may have been skewed by the high recurrence rate
in the control group (43) and this data was not supported by
further studies (44,45). Similarly disappointing results were
noted for neoadjuvant therapy as Matthay and colleagues
demonstrated that preoperative injection of BCG into NSCLC
did not affect the disease-free interval or prolong survival (46).
The discovery that, similar to malignant melanoma, NSCLC
can express tumor associated antigens led to an ever increasing
interest in the development of active immunotherapy protocols
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utilizing antigen specific immunotherapy. A few investigators
have attempted to modify whole tumor cell vaccines to render
them more immunogenic prior to patient administration in
order to stimulate an anti-tumor immune response. The GVAX
vaccine consists of autologous tumor cells engineered to express
granulocyte monocyte colony stimulating factor (GM-CSF),
which functions to enhance the production and migration
of granulocytes such as neutrophils and monocytes with
subsequential initiation of a tumor-specific immune response.
Such treatment has been shown in animal models to increase
the immunogenicity of certain tumors, especially malignant
melanoma (47). Based on this data several early phase trials
have been conducted using variable immunization protocols
consisting of irradiated autologous NSCLC cells transduced with
replication incompetent adenovirus expressing GM-CSF. One
of the trials, reported in 2004, demonstrated encouraging results
as three of the 33 patients with advanced disease had durable
and complete responses, one patient had a minor response, and
nine demonstrated a mixed response or disease stability (48).
Interestingly a survival advantage was noted in patients receiving
tumor vaccine secreting high levels of GM-CSF compared to
those secreting lower levels. Based on this preliminary data other
therapeutic strategies utilizing GVAX have been described (49).
Mucin-1 (MUC-1) is a protein normally expressed on
secretory epithelial cells and is present in multiple epithelial
cancers, including NSCLC (50). This mutated protein might
be an ideal target for active immunotherapy as it is antigenically
distinct from that found in normal tissue and functions as an
oncogene (51,52). Based on this preliminary data a phase IIb
study of patients with IIIa/IV stage lung cancer was conducted
randomizing patients to immunization with a synthetic peptide
designed to mimic the most antigenic portion of MUC-1
(L-BLP-25), or best supportive care. Eight weekly injections
were followed by maintenance immunization every 6 weeks
after standard first line chemotherapy and a single dose of
cyclophosphamide. Of the 171 patients in the trial those in the
immunization arm demonstrated a trend towards longer median
survival compared to the best supportive care group (17.4 vs. 13
months) but this trend did not reach statistical significance (53).
Such data, while limited, were encouraging and served as the
foundation for a multicenter randomized double blind placebo
control phase III trial in patients with unresectable stage III
disease (START trial).
MAGE-3 (melanoma associated antigen E-3) is a commonly
expressed cancer testis antigen that is not present in normal
adult tissue but is expressed on multiple malignancies including
NSCLC (54). Like multiple other TAA it was initially identified
in malignant melanoma based on its ability to stimulate
autologous cytotoxic T lymphocytes (55). Aside from its
restriction to extragonadal malignant tissue in the adult, MAGE3 is unique as this protein contains epitopes that can be presented
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by both MHC Class I and MHC Class II histocompatibility
antigens. Thus the ability of this TAA to activate both CD8+ and
CD4+ cytotoxic T lymphocytes may offer a unique approach to
stimulate a broad tumor-immune response using whole protein
vaccination as a form of antigen specific immunotherapy (56,
57). Based on these findings a phase II trial was performed
randomizing patients with completely resected MAGE-3 positive
stage IB and II NSCLC to either post-operative vaccination
with recombinant MAGE-3 protein or placebo. When reported
in 2007 a total of 30.6% patients in the vaccine arm and 43.3%
in the placebo arm had recurred (58). While these differences
did not reach statistical significance the data did suggest a trend
of improved outcomes in the vaccination group and only few
vaccine related side effects were recorded. Such reassuring data
led to the implementation of a larger phase III trial adjuvant
therapy trial, powered to detect differences in survival (5). The
MAGRIT study (MAGE-A3 Adjuvant Non-Small Cell Lung
Cancer Immunotherapy) is designed to enroll 2,270 MAGE-A3
positive patients after anatomic resection of stage IB, II, or IIIA
NSCLC. All patients will be randomized in a 2:1 fashion to
receive either the vaccine or placebo with a clinical end point of
disease free survival (59).
Another very novel approach designed to harness the power
of the immune system to treat lung cancer has been advanced
by a group from Cuba. Clinical application of this approach is
based on the finding that certain subsets of NSCLC express
the epidermal growth factor (EGF) receptor and inhibition of
this signaling pathway has been shown to have a therapeutic
effect (60). The EGF vaccine is produced in the Center of
Molecular Immunology in Havana, Cuba and is composed of
recombinant EGF chemically conjugated to the P64 Neisseria
meningitides recombinant protein adjuvant. The clinical
efficacy of this vaccination strategy has been recently reported
in a large randomized phase II trial (61). In this trial a total of
eighty patients with stage IIIB/IV NSCLC were randomized
to receive either vaccination or best supportive care after
finishing first line chemotherapy. While few side effects were
observed in the vaccinated group over half of the vaccinated
patients demonstrated a good anti-EGF antibody response with
a significant decrease in the serum EGF concentration. There
was a trend for improved survival in the vaccination group that
reached statistical significance in patients younger then 60 years
of age. This very novel line of investigation offers the opportunity
to target other cytokine or chemokine pathways responsible for
growth and maintenance of lung cancer.
Multiple other trials targeting TAA in NSCLC, such
as carcinoembryonic antigen (62) and HER-2/neu (63),
have been described and are currently in clinical trials.
While recent dramatic success with adoptive cell therapy
has been demonstrated for malignant melanoma (26) such
strategy has not yet been adapted to the field of lung cancer
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immunotherapy due to the lack of a well-defined and established
immunodominant tumor antigen. Perhaps success in clinical
trials using vaccination with defined peptides or whole proteins
will pave the way for adoptive cell therapy in the future.
Unlike NSCLC, small-cell lung cancer (SCLC) represents
only 15-20% of all primary malignancies the lung. SCLC is
usually a systemic disease at the time of diagnosis and only
anecdotal long-term survival has been reported. Even limited
disease, although initially responsive to chemo and radiation
therapy, often recurs (64,65). Based on these reasons biologic
therapy, such as immunotherapy, that can offer a long-term
tumor-specific response may be an ideal treatment modality for
this malignancy. Gangliosides are glycolipid components of the
plasma membrane that play an integral role in multiple biologic
functions. Compared to the normal cellular components of
the lung, neutral glycolipids are more prevalent in SCLC (66).
While poorly immunogenic in and of themselves, these antigens
can be successfully targeted by anti-idiotypic antibodies.
This form of immunotherapy takes advantage of the fact that
“secondary” antibodies raised against a primary antibody to a
defined antigen, even one of low affinity, will mimic epitopes
present in the original antigen in the hypervariable region of
the immunoglobulin. Administration of such anti-idiotypic
antibodies can then be used to generate both a humeral and
cellular TAA-specific immune response as the antibody itself acts
as an antigen (67,68). GD3 is a ganglioside present in tumors of
neuroectodermal origin including small cell lung cancer. While
itself poorly immunogenic (69), the anti-idiotype antibody to
this antigen (Bec2) produces a detectable anti-GD3 immune
response in as many as one-third of the treated patients (70,71).
A small pilot study of Bec2 vaccination combined with BCG
performed at Memorial Sloan-Kettering Cancer Center, revealed
a surprisingly positive response in the 15 treated patients and
acted as a nidus for a large randomized prospective trial (72).
Such a study was performed between 1998 and 2002 as 515
patients from 120 institutions in 17 countries with limited SCLC
were prospectively randomized to receive either vaccination with
Bec2 and a BCG adjuvant or observation alone after completing
induction chemoradiotherapy. When published in 2005 the
investigators were unable to detect an improvement in overall
survival, progression-free survival, or quality of life in those
in the vaccination arm (4). While a trend towards prolonged
survival was detected in the one third of patients who developed
a detectable humoral immune response to the vaccination, this
did not reach statistical significance. Toxicity was mostly related
to local skin-site irritation with occasional systemic effects
such as lethargy, arthralgia, and myalgia. Thus while this Bec2
vaccination trial presented an overall negative result the potential
for vaccination and immune-based therapy as an adjuvant
method for treating SCLC remains a future possibility if vaccines
capable of producing a better immunologic response can be
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developed.

Limitations and future directions
Immune based therapy for the treatment of solid cancer remains
an exciting approach that is quickly making headway from the
laboratory to the clinic. A cautionary and rational approach
needs to be taken, however, in order to prevent negative results
from halting progression of this field. First of all the potential for
autoimmune disease resulting from successful immunotherapy
of what is essentially altered self requires a cautious approach
to clinical experimentation. Even with current therapy
autoimmune vitiligo is often a complication of immunotherapy
for malignant melanoma and the use of allogenic bone marrow
transplantation as a mechanism of immunotherapy for leukemia
is often complicated by graft vs. host disease (73-75). Lessons
learned from notable examples such as the National Emphysema
Treatment Trial of lung volume reduction surgery, or the
recent human gene therapy trial for ornithine transcarbamylase
deficiency complicated by a patient death, demonstrate that
patient selection is critical for maintaining public enthusiasm and
support for clinical trials (76-78). Second of all it is important to
note that multiple current trials of immune based therapy enroll
patients with residual bulky primary or metastatic disease. Such
a strategy is counterintuitive to data demonstrating that tumor
volume directly impacts the ability to mount a successful tumorspecific immune response (79) . It also goes against experimental
data, from out laboratory as well as others, which demonstrate
that tumor associated stromal cells, both radiosensitive
hematopoietic myeloid cells and radioresistant endothelial cells,
can influence the tumor immune response (80-82). Thus a
potential therapeutic approach might combine immunotherapy
with complete gross tumor resection or aggressive debulking in
order to target minimal residual disease in the adjuvant setting.
Patient enrollment in the MAGRIT trial described above, for
example, is limited only to those with completely resected
disease, thus avoiding the immunologic barriers imposed by a
bulky tumor mass (58,59).

Summary
Unlike the case for malignant melanoma, immunotherapy
for NSCLC lags behind in both experimental and clinical
development. In fact most clinical trials are based on successful
therapy defined in preclinical models for malignant melanoma.
It is possible, however, that lung cancer may not respond to
similar immunotherapy strategies. Since the lung is a naturally
tolerogenic organ and intratracheal instillation of antigen is
a successful and accepted method for induction of tolerance
(83), it is possible that lung cancer directed immunotherapy
needs to be routinely combined with strategies to downregulate
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mechanisms of tolerance induction (33). It is also possible that
tumor immunoediting, or the elimination of immunodominant
antigens by the immune system, is highly prevalent in lung
cancer, resulting in resistance to immunotherapy (12). It is
however, not inconceivable that lung cancer develops completely
independent of immunologic influences and remains completely
invisible to the immune system. If this were to be the case other
strategies, such as targeted therapy of growth factor receptors,
might be necessary for adjuvant treatment of lung cancer instead
of immunotherapy (60).
Inbred mice offer an efficient and reproducible method
to study carcinogen-induced lung cancer as a highly reliable
model of lung adenocarcinoma exists. A single injection of
urethane leads to the development of early adenomatous
tumors in the lung within 10 weeks with progression to fully
invasive adenocarcinoma after 32 weeks (84). The progression
of such cancers from hyperplasia to benign adenoma to fully
invasive adenocarcinoma with metastatic potential mimics
progression of human disease. Interestingly multiple studies
have defined different strains of mice as either tumor-susceptible
“high-responders” (A/J for example) or tumor resistant “low
responders” (C3H He/J for example) with 100% of susceptible
animals and few resistant ones developing tumors after injection
of carcinogen (85). This variability in strain susceptibility to
induction of lung adenocarcinoma suggests that inherent genetic
factors may alter the development and/or progression of NSCLC
independent of carcinogen administration or the environment
(85). The use of such models to develop a better understanding
of lung cancer immunology and immune evasion, as has been
done for malignant melanoma, might facilitate a more rational
approach toward lung cancer immunotherapy.
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